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Abstract
Background: Infected necrosis complicates 10% of all acute pancreatitis episodes and is associated with 15–20%
mortality. The current standard treatment for infected necrotizing pancreatitis is the step-up approach (catheter drainage,
followed, if necessary, by minimally invasive necrosectomy). Catheter drainage is preferably postponed until the stage of
walled-off necrosis, which usually takes 4 weeks. This delay stems from the time when open necrosectomy was the
standard. It is unclear whether such delay is needed for catheter drainage or whether earlier intervention could actually
be beneficial in the current step-up approach. The POINTER trial investigates if immediate catheter drainage in patients
with infected necrotizing pancreatitis is superior to the current practice of postponed intervention.
Methods: POINTER is a randomized controlled multicenter superiority trial. All patients with necrotizing pancreatitis are
screened for eligibility. In total, 104 adult patients with (suspected) infected necrotizing pancreatitis will be randomized
to immediate (within 24 h) catheter drainage or current standard care involving postponed catheter drainage.
Necrosectomy, if necessary, is preferably postponed until the stage of walled-off necrosis, in both treatment arms. The
primary outcome is the Comprehensive Complication Index (CCI), which covers all complications between randomization
and 6-month follow up. Secondary outcomes include mortality, complications, number of (repeat) interventions, hospital
and intensive care unit (ICU) lengths of stay, quality-adjusted life years (QALYs) and direct and indirect costs. Standard
follow-up is at 3 and 6months after randomization.
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Discussion: The POINTER trial investigates if immediate catheter drainage in infected necrotizing pancreatitis reduces
the composite endpoint of complications, as compared with the current standard treatment strategy involving delay of
intervention until the stage of walled-off necrosis.
Trial registration: ISRCTN, 33682933. Registered on 6 August 2015. Retrospectively registered.
Keywords: Necrotizing pancreatitis, Infection, Step-up approach, Timing, Drainage, Complication, Randomized
controlled trial
Background
Acute pancreatitis is one of the most common gastrointes-
tinal conditions requiring acute hospital admission [1].
Around 20–30% of these patients develop necrotizing pan-
creatitis [2]. Infected necrotizing pancreatitis occurs in a
third of these patients and is associated with 15–20%
mortality [3, 4], despite radiological, endoscopic or surgical
interventions [3–6]. The current, 2013 international treat-
ment guidelines [7, 8] recommend a step-up approach,
based on the results of the Dutch PANTER trial [3]. The
first step of this step-up approach is catheter drainage,
preferably once the (extra) pancreatic collection has orga-
nized and has become fully encapsulated (walled-off necro-
sis). This process is usually complete 4 weeks after the
onset of disease. During this time, intravenous antibiotic
treatment is used which may obviate the need for any
intervention in a small subset of patients [4]. If catheter
drainage does not resolve the clinical signs of infection and
sepsis, surgical [3] or endoscopic [9] necrosectomy is per-
formed as the next step.
Postponing all interventions for infected necrosis until
the stage of walled-off necrosis has been standard practice
for many years. The rationale for this delay lies in the pre-
vention of the “extra hit” (i.e. a pro-inflammatory reaction)
of open surgery in these already critically ill patients, and
in the relationship between early open necrosectomy and
mortality [10]. In line with this practice, catheter drainage
in the current step-up approach has also been postponed
until the stage of walled-off necrosis. Meanwhile, intraven-
ous antibiotics are administered to reduce systemic illness
from the infected necrosis, which may lead to increased in-
cidence of Candida infections and antibiotic resistance
[10]. Notably, several observational studies have suggested
that encapsulation is not mandatory for safe and successful
catheter drainage [3, 11–15]. In other conditions, such as
pancreatic fistula after pancreatic resection, early (percu-
taneous) catheter drainage has also proven to be safe and
successful [16]. Furthermore, an international survey
among expert pancreatologists demonstrated “equipoise”
between immediate and postponed catheter drainage of in-
fected necrotizing pancreatitis [17]. The aim of immediate
catheter drainage is to prevent further clinical
deterioration.
Methods
The trial protocol is written in accordance with the Stand-
ard protocol items: recommendation for interventional
trials (SPIRIT) guidelines (see Fig. 1 and the Additional
file 1: SPIRIT checklist) [18].
Study aim
The POINTER trial aims to determine whether immediate
catheter drainage in patients with (suspected) infected
necrotizing pancreatitis is superior to the current standard
of postponed catheter drainage with regard to clinical out-
come and cost-effectiveness. The hypothesis is that
pro-active diagnosis of infected necrosis and immediate
catheter drainage prevents further clinical deterioration in
these patients, reducing complications and possibly death,
and reduces length of hospital stay and costs, as compared
to postponing catheter drainage using antibiotics, prefera-
bly until the stage of walled-off necrosis.
Study design and setting
POINTER is a randomized controlled multicenter super-
iority trial, including hospitalized adult patients with
proven or suspected infected necrotizing pancreatitis. In
total, 25 centers are participating in the trial, including all
8 Dutch university medical centers. Endpoints are
assessed by an adjudication committee, blinded to the
assigned treatment arm, based on clinical case descrip-
tions and endpoint definitions. The Data and Safety Moni-
toring Committee (DSMC) monitors patient safety.
Inclusion criteria (see Additional file 2: Table S1 and
Additional file 3: Table S2)
The inclusion criteria are:
– Proven infected necrotizing pancreatitis (0–35 days
after the onset of disease) or clinical suspected
infected necrosis (15–35 days after the onset of
disease)
– Catheter drainage of the necrotic collection is
technically feasible, as deemed by the expert panel
and/or treating physician (i.e. enough encapsulation
and liquefaction)
– Age ≥ 18 years
Grinsven et al. Trials          (2019) 20:239 Page 2 of 10
Exclusion criteria
The exclusion criteria are:
– Onset of acute pancreatitis > 35 days ago
– Indication for emergency laparotomy because of an
abdominal catastrophe (e.g. bleeding, bowel
perforation or abdominal compartment syndrome)
– Previous retroperitoneal intervention for necrotizing
pancreatitis (ascites drainage is permitted and
(emergency) laparotomy without opening the bursa is
permitted)
– Documented chronic pancreatitis (according to the
M-ANNHEIM criteria [36], since this is a different
disease entity)
Treatment groups
All patients with signs of infected necrotizing pancrea-
titis are pro-actively assessed for the presence of infected
Fig. 1 SPIRIT schedule of enrollment, interventions, and assessments. *In the case of no clinical improvement. βBaseline variables: age, sex, center,
body mass index, etiology of pancreatitis, American Society of Anesthesiologist’s classification, co-morbidity, disease severity, suspected or proven
infected necrosis, time from admission to randomization, time from admission to tertiary referral. ^Primary outcome: Comprehensive Complications
Index. #Secondary outcomes: mortality, complications, number of (repeat) interventions, hospital and intensive care unit lengths of stay, quality-
adjusted life years and direct and indirect costs
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necrosis, either by imaging (gas configurations), fine-
needle aspiration (FNA), or clinical signs of infection,
which may include persistent organ failure. See Add-
itional file 4: Figure S1 for the inclusion flowchart. FNA
is only used on indication and not as a screening tool.
Patients who fulfill the eligibility criteria are randomly
assigned to group A or B. Since diagnosing infected ne-
crosis and making decisions on whether to perform in-
vasive intervention in these patients are challenging, the
Dutch pancreatitis expert panel [19] is 24 hours per day,
7 days per week, to assess indications for intervention
and eligibility for randomization as was done in the
PANTER [3] and TENSION [9] trials.
Intervention group (A)
Group A will receive immediate catheter drainage within
24 h after randomization, while starting (or continuing)
antibiotic treatment. In the case of no clinical improve-
ment within 72 h thereafter, the possibility of additional
drainage is evaluated, including drain revision or drain up-
sizing. In the case of no clinical improvement thereafter,
and no possibilities for additional catheter drainage, min-
imally invasive necrosectomy is performed once the (extra)
pancreatic collection has developed into walled-off necro-
sis. No clinical improvement is defined as new organ fail-
ure or 2/3 parameters that do not decrease (temperature,
C-reactive protein (CRP) and leukocyte count). See flow-
chart in Additional file 4: Figure S1.
Control group (B)
Group B will have postponed catheter drainage and re-
ceive antibiotics, preferably until the (extra) pancreatic
necrotic collection has reached the stage of walled-off ne-
crosis. In case of no clinical improvement within 72 h after
drainage, the possibility of additional drainage is evaluated,
including drain revision or drain upsizing. In case of no
clinical improvement thereafter and no possibilities for
additional catheter drainage, minimally invasive necrosect-
omy is performed. No clinical improvement is defined as
new organ failure or 2/3 parameters that do not decrease
(temperature, CRP and leukocyte count). See flowchart in
Additional file 4: Figure S1.
Diagnosing infected necrosis
All patients with signs of infected necrotizing pancrea-
titis are screened for eligibility (Additional file 4: Figure
S1). We differentiate between diagnosis of infected ne-
crosis within the first 14 days after onset of disease and
diagnosis thereafter. In the first 14 days a proven infec-
tion is mandatory, as in this early course of the disease it
is impossible to distinguish systemic inflammatory re-
sponse syndrome (SIRS) from sepsis. This proof requires
either a positive gram stain or culture from FNA or gas
configurations in the (peri) pancreatic collection with
necrosis, on imaging (contrast enhanced computed tom-
ography (CECT) or magnetic resonance imaging (MRI)).
In the case of unclear signs of infection, percutaneous
FNA is performed in patients with necrotizing pancrea-
titis within 14 days after onset of disease who have had
clinical signs of infection (i.e. new (multiple) organ fail-
ure or 2/3 parameters raised: temperature, CRP or
leukocyte count) for 2 days consecutively . After the first
14 days, clinical signs of infection suffice for diagnosing
infected necrosis (having no other focus for infection,
e.g. pneumonia), based on our experiences in previous
trials [3, 9]. Obviously, in the case of clinical doubt, FNA
is still allowed after the first 14 days. The presence of gas
in the (extra) pancreatic necrosis on CECT is considered
proven infected necrosis in all patients, regardless of the
disease stage (i.e. before or after 14 days).
Supportive treatment
Current standard management of acute (necrotizing)
pancreatitis is extensively described in the International
Association of Pancreatology (IAP)/American Pancreatic
Association (APA) guidelines of 2013 [7]. These inter-
national guidelines have been adopted by the Dutch
Pancreatitis Study Group (DPSG) and the national pro-
fessional organizations involved. In accordance with
these guidelines, patients receive fluid resuscitation, pain
management and enteral feeding (or oral, if enteral feed-
ing is not tolerated). Antibiotic prophylaxis is not given.
The source of infection will be investigated in patients
with clinical signs of infection and deterioration, by
means of analysis of blood, urine, sputum, and ascites
and by diagnostic imaging (e.g. chest x-ray and abdom-
inal CECT). Once the focus of infection is identified, tar-
geted antibiotics are given or, in when there infected
necrosis is suspected and there is persistent deterior-
ation, broad spectrum antibiotics with optimal tissue
penetration are started empirically. The latter usually
consists of meropenem or imipenem, based on the local
antibiotics protocol.
Step-up approach
Both a percutaneous surgical and an endoscopic step-up
approach are permitted in the POINTER trial, depend-
ing on the location of the necrotic collection(s), the ex-
tent of encapsulation and the preference of the treating
physician. Transluminal (transgastric or transduodenal),
endoscopic or percutaneous catheter drainage via the
retroperitoneal route may be performed. In the case of
no clinical improvement within the first 72 h after initial
catheter drainage, an additional or upsizing drainage
procedure is performed (Additional file 4: Figure S1).
Necrosectomy is performed when there is no clinical im-
provement after this second drainage procedure and no
further possibilities for optimized or additional drainage.
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After percutaneous catheter drainage, additional necro-
sectomy should be performed surgically (e.g. videoscopic
assisted retroperitoneal debridement (VARD)) and after
endoscopic transluminal drainage, endoscopic translumi-
nal necrosectomy is performed. Additional catheter
drainage or necrosectomy may be performed using the
“other” approach only when (additional) necrotic collec-
tions are not technically approachable using the stand-
ard second step. Both step-up approaches are performed
to conform with the PANTER and TENSION trial pro-
tocols [3, 9]; see also Additional file 5: Figure S2 and
Additional file 6: Figure S3. Randomized studies can be
influenced by underestimation of learning curves, there-
fore in the POINTER trial the participating centers must
have documented expertise, defined as having performed
at least 10 independent VARD procedures, 10 independ-
ent endoscopic transluminal drainage procedures and 10
independent endoscopic transluminal necrosectomies.
This number has been chosen to achieve a balance be-
tween volume and feasibility, and from experience with
other trials of our study group including necrotizing
pancreatitis patients [3, 9]. In the case of there being in-
sufficient local experience available (e.g. during week-
ends), the patient is transferred to a tertiary referral
center with sufficient experience.
Primary endpoint
The primary endpoint is the Comprehensive Complica-
tions Index (CCI) [20, 21], including all complications
other than pre-existent complications (e.g. treatment for
infected (extra) pancreatic necrosis) occurring after
randomization until 6 months after randomization, and
graded according to the Clavien-Dindo classification.
These complications are assessed by an adjudication
committee, blinded for assigned treatment arm, based
on clinical case descriptions using definitions.
Secondary endpoints
Secondary endpoints are mortality, new-onset (multiple)
organ failure, bleeding requiring intervention, perfor-
ation of a visceral organ requiring intervention, entero-
cutaneous and pancreatic fistula, incisional hernia
(including burst abdomen), wound infections, endocrine
and exocrine pancreas insufficiency, number of patients
with severe complications (Clavien-Dindo III or higher),
number of patients per Clavien-Dindo classification,
number of surgical, endoscopic and radiological (repeat)
interventions, length of hospital stay, length of ICU ad-
mission, quality-adjusted life years (QALYs) and total
direct and indirect costs (see Additional file 7 for rele-
vant definitions). Also, for mutual comparison, the pri-
mary endpoint of the previous PANTER trial will be a
secondary endpoint of the POINTER trial (i.e. a com-
posite of major complications: new-onset multiple organ
failure, enterocutaneous fistula or perforation of a vis-
ceral organ requiring intervention, intra-abdominal
bleeding requiring intervention or death during admis-
sion or during the 3 months after discharge) [3].
Sample size
The sample size was calculated based on the primary
endpoint, the CCI. A mean CCI score of 40 (with stand-
ard deviation of 27) for postponed catheter drainage is
based on the number of complications identified in the
step-up arm of the PANTER trial [3] and TENSION trial
[9]. Analysis by Student’s t test will have 80% power to
detect a clinically relevant reduction of 15 to a CCI score
of 25 [21] at a significance level of 0.05; for a sample size
that equals 2 × 51, this will result in 102 evaluable pa-
tients. Assuming a dropout rate of about 2%, then 104
patients need to be included. A drop-out rate of 2% is
relatively low, but was chosen from experience with
other trials in our study group including patients with
necrotizing pancreatitis, in which no there was no loss
to follow-up or drop-outs [3, 9].
Randomization, blinding and treatment allocation
Patients are randomized using a centrally operated com-
puter (ALEA system) with variable block randomization
for allocation concealment between group A (immediate
catheter drainage) and group B (postponed catheter
drainage). Stratification at randomization is applied for the
following factors: presence of organ failure (yes versus no),
disease duration (day 0–20 versus day 21–35) and center
(expected high number of included patients versus other
centers). For randomization of a patient, physicians can
contact the study coordinator via telephone (www.pancrea-
titis.nl) 24 h per day, 7 days per week in order to check the
eligibility criteria and to verify whether informed consent
has been obtained. Blinding of patients and physicians to
treatment strategy is not feasible, since both treatments are
highly different timing-wise. Patients are coded by a
numeric randomization code (anonymized).
Follow up
The follow-up duration is 6 months from randomization.
Outpatient follow-up visits take place at the discretion
of the responsible physician, but in any case, follow up
at 3 and 6months after randomization can be consid-
ered as standard care. All patients undergo imaging
(preferably CECT) at 3 and 6months post
randomization. Furthermore, exocrine and endocrine
pancreatic function is measured at these points in time,
with blood glucose measurements and fecal elastase
tests, respectively. No blood or fecal samples are stored
at the DPSG data center. The treating physician is re-
sponsible for the application, interpretation and treat-
ment when needed. Also, every patient receives a
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combined questionnaire at home (Short Form-36
(SF-36) [22], Euroqol 5 dimensions (EQ-5D) [23], iMedi-
cal Consumption Questionnaire (iMCQ) [24] and iPro-
ductivity Cost Questionnaire (iPCQ) [25]) at 3 and 6
months. Data from patient records are collected until 6
months post randomization.
Baseline values
Baseline criteria (all < 24 h prior to randomization) are
age, sex, center, body mass index, etiology of pancreatitis,
American Society of Anesthesiologist’s (ASA) classifica-
tion, co-morbidity, disease severity (SIRS, ICU admission,
single or multiple organ failure, Acute Physiology and
Chronic Health Evaluation (APACHE) II score, Multiple
Organ Dysfunction Score (MODS) [26], Sequential Organ
Failure Assessment (SOFA) score [27], CRP), CT severity
index (CTSI), suspected or proven infected necrosis, time
from admission to randomization (days) and time from
admission to tertiary referral (days).
Statistical analysis
All randomized patients are evaluated for primary and
secondary endpoints at 6 months after randomization.
Using primary source data, an adjudication committee
will assess the occurrence of the primary and secondary
outcomes blinded to treatment allocation, after the last
patient has completed the predefined follow up 6
months after randomization.
The primary analysis is based on intention-to-treat prin-
ciples. For exploratory reasons per-protocol analysis will
also performed. A tabular listing of all patients excluded
from the intention-to-treat populations will be provided
together with the reasons for exclusion. For the
intention-to-treat population the protocol deviations in
each randomization arm are listed. Predefined subgroup
analyses will be performed in patients with and without
(multiple) organ failure and disease duration (cutoff 20
days) at the time of randomization and per center (high
expected number of included patients and other centers).
All analyses will be performed in SPSS for Windows
or SAS System for Windows. All data handling and ana-
lyses will be saved in a syntax/program file. Results will
be presented with all centers combined. A two-tailed p
value <0.05 is considered statistically significant. No cor-
rections for multiple tests will be applied.
The primary outcome is a sum of all complications
that are weighted for their severity (multiplication of the
median reference values from patients and physicians),
the CCI [20, 21]. Comparison of the primary endpoint
will be expressed in terms of the absolute difference in
mean CCI score and standard deviation (SD). Subse-
quent analyses will be directed at the secondary end-
points. Data will be presented as mean ± SD and in the
case of skewed distributions as median and range. Values
will be compared using Student’s t test, Wilcoxon’s rank
sum test, the chi square (χ2) test or Fischer;s exact test,
as appropriate. In the event of imbalance between
groups at baseline, regression analysis will be used to
correct for the effect of the covariates.
The economic evaluation will address the question of
whether or not immediate catheter drainage in patients
with infected necrosis is cost-effective compared to the
current management of postponed catheter drainage. A
cost-effectiveness analysis and a cost-utility analysis will
be performed, both from a societal perspective. The pri-
mary outcome parameters in the cost-effectiveness and
cost-utility analyses, respectively, are the costs per unit
of the CCI score and the costs per QALY.
Monitoring and quality assurance
Clinical trial monitoring is performed by an independent
monitor. The trial monitor checks and verifies documents
and reports in the trial patients’ electronic or paper records
at every site. The frequency may be changed based on the
total enrollment period and enrollment rate. The monitor
checks the site files according to the Medical Research In-
volving Human Subjects Act (WMO)/Good Clinical Prac-
tice (GCP) standards, as to whether and how essential
documents are collected/administered and verifies all re-
ported severe adverse events (SAEs). Also, the monitor
verifies protocol compliance. A monitoring report is com-
piled after each monitoring visit at each specific site.
Safety
Physicians who are involved in the trial will be asked to re-
port all adverse events to the coordinating investigator.
The independent Data Safety Monitoring Committee
(DSMC) will evaluate safety parameters at regular inter-
vals. The DSMC consists of five members: two surgeons, a
gastroenterologist, a radiologist and an epidemiologist.
Evaluations are planned after patient number 25, 50 and
75 have completed their 6-month follow up. Deceased pa-
tients and every SAE that is possibly trial-related will be
discussed unblinded by the DSMC, 25 patients at a time
in 4 sessions. During the inclusion period of the study the
DSMC performs interim analyses only on safety. Only for
safety reasons as assessed by the DSMC will the
POINTER trial be prematurely terminated. There will be
no interim analysis of treatment effect. Adverse events are
reported using the online module (https://www.toetsin-
gonline.nl) of the Dutch Central Committee on Research
involving human subjects.
Discussion
Infected necrosis is a potentially lethal complication of
acute pancreatitis, typically requiring invasive interven-
tion. The treatment of infected necrotizing pancreatitis
is associated with lengthy hospital stay and high costs.
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The POINTER trial is the first randomized controlled
trial designed to determine the optimal timing of cath-
eter drainage in infected necrotizing pancreatitis: i.e.
immediate or postponed, once walled-off necrosis has
occurred.
According to current evidence-based international
guidelines [7, 8], suspected or proven infected necrosis
in patients with clinical signs of infection is an indication
for invasive intervention. There should be a strong re-
luctance towards intervening in sterile collections [7,
28]. Currently, intervention is advised when the infected
necrosis has become walled-off, which occurs typically 4
weeks after the onset of disease [29]. This practice of
postponing interventions until the stage of walled-off ne-
crosis is based on literature published when open necro-
sectomy was the standard intervention [10, 30, 31]. Early
necrosectomy is now recognized as having a major im-
pact in the critically ill patient, whereas postponed
necrosectomy allows the immune system to recover
from the pro-inflammatory response due to pancreatitis.
Since the step-up approach is now considered stand-
ard of care, the issue of the optimal timing of catheter
drainage has become highly relevant. Current literature
reports that 35–64% of patients with infected necrotiz-
ing pancreatitis can be treated with catheter drainage
alone, without the need for invasive necrosectomy [3, 5].
Therefore, several expert pancreatologists have stated
that they already practice immediate catheter drainage
in patients with infected necrosis. In a recent inter-
national survey performed in preparation for this study,
55% of expert pancreatologists stated that they typically
postpone catheter drainage by using antibiotics, whereas
the other 45% proclaimed to drain immediately after
diagnosing infected necrosis [17]. Thus, in practice im-
mediate catheter drainage is already being performed in
individual patients, regardless of the effect of antibiotics
alone or the degree of encapsulation: (percutaneous)
catheter drainage in infected necrosis has been described
retrospectively in several cohorts [32] at a median of 2
weeks (9–15 days) after the onset of disease instead of at
4 weeks (28 days).
Patient outcomes were significantly better in the
step-up-approach arm of the PANTER trial compared to
the control group (primary open necrosectomy), but
mortality (19%) did not differ between the two groups
[3]. The POINTER trial assesses whether early detection
of infected necrosis and immediate catheter drainage im-
prove outcomes, to further reduce mortality and mor-
bidity. Earlier intervention may prevent patients from
further deterioration while often waiting several weeks
before undergoing invasive intervention, and thereby re-
duce complications and length of hospital stay and im-
prove patient quality of life. In the control group, the
effect of antibiotics is awaited while letting the (extra)
pancreatic necrotic collections become walled-off. Anti-
biotic treatment alone may suffice in a small minority of
patients [4], which is another possible benefit for the
control group.
Infected necrosis can be diagnosed on imaging (e.g.
CECT) by the presence of gas in the (extra) pancreatic
necrotic collection, irrespective of the source of the gas
(i.e. through gas-forming bacteria or loss of integrity of
the gastrointestinal tract). Collections with gas are seen
in up to 42% of patients with infected necrosis [33] and
can occur in every phase of the disease [34, 35]. Infected
necrosis can also be confirmed by a positive gram stain
or culture gathered with FNA. In a recent study, infected
necrosis was confirmed by FNA in 86% (of 28 patients),
which was similar to diagnosis based on clinical symp-
toms (80% of 92 patients) or gas identified on imaging
(94% of 88 patients) [33]. Until recently, FNA was not
routinely used in the Netherlands for diagnosing in-
fected necrosis [17], as its outcome did not influence
treatment because invasive intervention was postponed
until the stage of walled-off necrosis, even in the case of
a positive culture. In the POINTER trial, however, it is
pivotal to detect infected necrosis as early as possible so
as to perform immediate drainage (group A). Differenti-
ating SIRS from sepsis is, however, very difficult in the
first 14 days of the disease. Therefore, in the absence of
gas on imaging but with clinical signs of infection in the
first 14 days, a positive gram stain or culture after FNA
is obligatory prior to randomization. Since the false
negative rate of FNA is relatively high [33], a second
FNA is advised in patients with persistent deterioration
and a primary negative FNA. Clinical signs alone are suf-
ficient to diagnose (suspected) infected necrotizing pan-
creatitis after the first 14 days [3].
After the first 14 days, clinical signs of infected necro-
sis are much more reliable. In the PANTER trial [3] it
was possible to attain 91% accuracy in the identification
of infected necrosis based on clinical criteria. Patients
can be randomized in the POINTER trial after the first
14 days, based on the clinical diagnosis of infected ne-
crosis, as was done in the PANTER trial [3].
Patients are randomized to undergo either immediate
(< 24 h) or postponed (in walled-off necrosis) catheter
drainage of infected collections. Both the surgical and
the endoscopic step-up approach are allowed, depending
on the location of the necrotic collection(s), the extent
of encapsulation and the preference of the treating phys-
ician. It is known that both approaches are effective and
safe and that not all (peri) pancreatic collections are ap-
proachable using a single technique [6, 9].
The CCI [20, 21] is the primary endpoint of the trial.
Patients with infected necrotizing pancreatitis often have
a long disease course with multiple complications, and
therefore the CCI score is considered a representative
Grinsven et al. Trials          (2019) 20:239 Page 7 of 10
tool to take into account all these complications. The in-
dividual complications (e.g. organ failure and mortality),
number of (repeat) interventions, hospital and ICU
lengths of stay, QALYs and direct and indirect costs are
also analyzed as secondary end points.
Patients are stratified based on organ failure at baseline,
since it is known that patients with organ failure have
poorer outcomes, as compared to patients with no organ
failure. Patients are also stratified on disease duration (cut-
off 20 days) since this is obviously related to the onset of
walled-off necrosis. Finally, patients are stratified on ex-
pected high versus low volumes of patient inclusion.
In conclusion, the POINTER trial is a multicenter ran-
domized controlled trial that investigates whether imme-
diate catheter drainage reduces the CCI in patients with
infected necrotizing pancreatitis, as compared to post-
poned catheter drainage.
Trial status
The trial was registered on 6 August 2015 as
ISRCTN33682933 (http://www.isrctn.com/ISRCTN33682933).
The first patient was randomized on 4 August 2015.
To date, 88 of the 104 patients have been randomized
and the inclusion of patients is on schedule.
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